Clin2
NCT07878585Possibly a fitNot yet recruiting

Herbal medicine plus prednisone for IgG4-related disease

IgG4 Related Disease

Treatments studied

Part of Immune system & allergy clinical trials.

This trial tests a combination of an herbal medicine (Tripterygium wilfordii) and the steroid prednisone to see if it helps control symptoms of IgG4-related disease, a condition where the immune system attacks your own organs. The study aims to find a more effective or safer treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
74 people
Ages
45 years to 79 years
Study type
Interventional

Who can take part

  • You are between 45 and 80 years old, and if you are a woman, you have gone through menopause
  • You have been diagnosed with IgG4-related disease according to specific medical criteria
  • Your disease is active, meaning you have symptoms in at least one organ that score 2 or higher on a disease activity scale
  • You have not been treated before, or your disease has come back after stopping previous treatment

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01670695Recruiting
Study people with IgG4-related disease in China

This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.

Beijing, Beijing Municipality
NCT07068165Recruiting· Phase 2/Phase 3
Lenalidomide for active IgG4-related disease

This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).

Beijing
NCT07148791Recruiting· Phase 2
CAR-T therapy for relapsed or refractory IgG4-related disease

This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.

Beijing, Beijing Municipality
NCT07061938Recruiting· Phase 1/Phase 2
Study of ACE1831 for patients with IgG4-related disease

This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.

Atlanta, Georgia
NCT07621939Not yet recruiting· Phase 2/Phase 3
Study of IMM0306 for IgG4-related disease

This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.

NCT05746689Not yet recruiting
Sirolimus for active IgG4-related disease

This trial tests a drug called sirolimus (which helps calm the immune system) for people with active IgG4-related disease. It may help reduce symptoms like swelling and pain if your current treatments are not working well.

Hear when a new IgG4-Related Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.